136 related articles for article (PubMed ID: 16468604)
1. [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].
Jancsó Z; Varga Z; Simay A; Ilyés I
Orv Hetil; 2005 Dec; 146(52):2629-33. PubMed ID: 16468604
[TBL] [Abstract][Full Text] [Related]
2. [Continuing care of patients with cardiovascular risk in general practice: patients with hypertension and their care].
Jancsó Z; Márton H; Simay A; Kovács E; Iléys I
Orv Hetil; 2006 Feb; 147(8):339-44. PubMed ID: 16579332
[TBL] [Abstract][Full Text] [Related]
3. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
Petrella RJ; Merikle E; Jones J
Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
[TBL] [Abstract][Full Text] [Related]
5. [Cardiovascular risk among patients of general practices, who are not in current acute care].
Jancsó Z; Márton H; Simay A; Ujhelyi I; Ilyés I
Orv Hetil; 2003 Jul; 144(29):1433-9. PubMed ID: 12939864
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of dyslipidemia in clinical practice].
Paragh G; Harangi M
Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
[TBL] [Abstract][Full Text] [Related]
7. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
[TBL] [Abstract][Full Text] [Related]
8. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
9. The treatment of dyslipidemia--what's left in the pipeline?
Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
[TBL] [Abstract][Full Text] [Related]
10. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
11. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
Turhan H; Yetkin E
Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
[TBL] [Abstract][Full Text] [Related]
12. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
13. Is lipid control necessary in hemodialysis patients?
Cheung AK
Clin J Am Soc Nephrol; 2009 Dec; 4 Suppl 1():S95-101. PubMed ID: 19996012
[TBL] [Abstract][Full Text] [Related]
14. Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort).
Gardette V; Bongard V; Dallongeville J; Arveiler D; Bingham A; Ruidavets JB; Amouyel P; Haas B; Ducimetière P; Ferrières J
Am J Cardiol; 2009 Feb; 103(3):381-6. PubMed ID: 19166693
[TBL] [Abstract][Full Text] [Related]
15. Managing dyslipidemia in chronic kidney disease.
Harper CR; Jacobson TA
J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
[TBL] [Abstract][Full Text] [Related]
16. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease.
Poussa H; Strandberg TE; Tikkanen I; Kauhanen P; Lepäntalo M
Scand Cardiovasc J; 2007 Jun; 41(3):138-41. PubMed ID: 17487761
[TBL] [Abstract][Full Text] [Related]
18. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
19. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
20. Contemporary management of dyslipidemia in high-risk patients: targets still not met.
Yan AT; Yan RT; Tan M; Hackam DG; Leblanc KL; Kertland H; Tsang JL; Jaffer S; Kates ML; Leiter LA; Fitchett DH; Langer A; Goodman SG;
Am J Med; 2006 Aug; 119(8):676-83. PubMed ID: 16887414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
